Toshihiro Ueda

Outcome in Acute Stroke with Successful Intra-Arterial Thrombolysis and Predictive Value of Initial Single-Photon Emission-Computed Tomography

This study investigates retrospectively, in selected patients, the ischemic outcome (reversible ischemia, infarction, and hemorrhage) and neurologic outcome of acute stroke treated with intra-arterial thrombolysis and the predictive value of pretreatment single-photon emission-computed tomography (SPECT). Thirty patients with complete recanalization within 12 hours were analyzed. The extent of ischemia was outlined on SPECT, and two CBF parameters were calculated: the ratio of ischemic regional activity to CBF in the cerebellum and the asymmetry index. Reversible ischemia, infarction, and hemorrhage were identified by comparing SPECT and follow-up computed tomography. Nine patients (30%) had no or small infarction, 14 (47%) had medium or large infarction, and seven (23%) had hemorrhage. Forty-two lesions were identified (22 reversible ischemia, 13 infarction, and 7 hemorrhage). Duration of ischemia, urokinase dose, disease type, and occlusion site were nonsignificant factors, whereas neurologic outcome and CBF parameters were significant among the three patient groups and three types of ischemic lesions. Ischemic tissue with CBF greater than 55% of cerebellar flow still may be salvageable, even with treatment initiated 6 hours after onset of symptoms. Ischemic tissue with CBF greater than 35% of cerebellar flow still may be salvageable with early treatment (less than 5 hours). Ischemic tissue with with CBF less than 35% of cerebellar flow may be at risk for hemorrhage within the critical time window. Pretreatment SPECT can provide useful parameters to increase the efficacy of thrombolysis by reducing hemorrhagic complications and improving neurologic outcome.

Clinical application of perfusion and diffusion MR imaging in acute ischemic stroke

With the advances in new neuroimaging modalities, the role of imaging of acute ischemic stroke has broadened and progressed from making diagnoses to providing valuable information for patient management. The goal of thrombolytic therapy for acute ischemic stroke should be to salvage the ischemic tissue reversibility that can respond to recanalization and avoid reperfusion of the dead (nonviable) tissue. It is essential to have rapid diagnostic modalities that can distinguish viable ischemic tissue from irreversibly damaged tissue, because there is a risk of reperfusion injury such as hemorrhagic complications with early intervention. Although diffusion magnetic resonance (MR) imaging has been reported to have a high sensitivity and specificity for acute ischemia in acute stroke patients without early reperfusion therapy, the capability to differentiate reversible from irreversible ischemia by diffusion MR imaging has not been established. Perfusion MR imaging techniques provide direct information on parenchymal perfusion status (adequacy of the collateral circulation) and may have the potential for providing important information about tissue viability and/or reversibility for selecting appropriate patients for thrombolytic therapy. J. Magn. Reson. Imaging 1999;10:305–309.

Diagnosis of microvasculopathy in CNS vasculitis: value of perfusion and diffusion imaging.

Functional imaging may come to play an important role in the evaluation of CNS vasculitis by demonstrating pathology on the microcirculatory level. A positive finding of microvascular ischemia may assist in the diagnosis of CNS vasculitis. More importantly, the demonstration of normal microcirculation may reliably exclude CNS vasculitis. J. Magn. Reson. Imaging 1999;10:310–313.

Current and future imaging of acute cerebral ischemia: assessment of tissue viability by perfusion imaging.

With the advances and availability of new imaging modalities, the role of imaging of acute stroke has been broadened from making diagnosis to providing valuable information for patient management. We need to have rapid diagnostic modalities that distinguish reversible ischemic tissue from irreversibly damaged tissue for successful thrombolytic therapy. Although diffusion imaging has been reported to have both high sensitivity and specificity for acute ischemia in clinical studies, previous reports do not conclude whether the diffusion abnormality is indicative of reversibly or irreversibly injured tissue. Perfusion imaging such as perfusion magnetic resonance imaging and single-photon emission computed tomography may have the potential for providing useful information that determines tissue viability and/or reversibility. Cerebral blood flow thresholds evaluated by pretreatment single-photon emission computed tomography provide important information that is potentially useful in the management of acute stroke patients with intra-arterial thrombolysis. Perfusion imaging, when combined with diffusion imaging, may thus be potentially useful in improving patient selection for thrombolytic therapy.

Revisiting Current Golden Rules in Managing Acute Ischemic Stroke: Evaluation of New Strategies to Further Improve Treatment Selection and Outcome

OBJECTIVE Advanced stroke imaging has generated much excitement for the early diagnosis of acute ischemic stroke (AIS) and facilitation of intervention. However, its therapeutic impact has not matched its diagnostic utility; most notably, lacking significant contributions to recent major AIS clinical trials. It is time to reexamine the fundamental hypotheses from the enormous body of imaging research on which clinical practices are based and reassess the current standard clinical and imaging strategies, or golden rules, established over decades for AIS. In this article, we will investigate a possible new window of opportunity in managing AIS through a better understanding of the following: first, the potential limitations of the golden rules; second, the significance of imaging-based parenchymal hypoperfusion (i.e., lower-than-normal relative cerebral blood flow [rCBF] may not be indicative of ischemia); third, the other critical factors (e.g., rCBF, collateral circulation, variable therapeutic window, chronicity of occlusion) that reflect more individual ischemic injury for optimal treatment selection; and, fourth, the need for penumbra validation in successfully reperfused patients (not in untreated patients). CONCLUSION Individual variations in the therapeutic window, ischemic injury (rCBF), and chronicity of vascular lesion development have not been comprehensively incorporated in the standard algorithms used to manage AIS. The current established imaging parameters have not been consistently validated with successfully reperfused patients and rCBF to quantitatively distinguish between oligemia and ischemia and between penumbra and infarct core within ischemic tissue. A novel paradigm incorporating rCBF values or indirectly incorporating relative rCBF values with higher statistically powered imaging studies to more reliably assess the severity of ischemic injury and differentiate reversibility from viability within the area of imaging-based parenchymal hypoperfusion may provide a more personalized approach to treatment, including no treatment of infarction core, to further enhance outcomes.

Selection Criteria for Intra-Arterial Thrombolytic Therapy by Initial SPECT

We determined the selection criteria for intra-arterial thrombolytic therapy by initial single-photon emission-computed tomography (SPECT) using 99mTc-HMPAO. We studied 30 patients who were obtained early complete recanalization of the internal carotid territory occlusion. The residual CBF of non-infarction, infarction and hemorrhagic lesions judged by follow-up CT scan was evaluated semiquantitatively by calculating two parameters with pretherapeutic SPECT: the ischemic regional activity to cerebellar activity ratio (R/CE ratio) and asymmetry index (AI). The patients neurological exam was evaluated according to the NIH stroke scale score. The patients were classified by follow-up CT into three groups: A) nine patients who had no or small infarction; B) fourteen patients who had medium or large cortical infarction; C) seven patients who had hemorrhagic transformation. No significant difference was observed in the interval from onset, UK doses, or site of occlusion between each group. However, the residual CBF and the NIH scores 1 month later in group C were significantly worse than those in group A or B. Forty-two lesions were identified (22 reversible ischemia, 13 infarction, and 7 hemorrahge). The residual CBF and neurological outcome were significant among three types of lesions. Tissue reversibility at any given time rather than duration of ischemia remains the most important factor to influence outcome. Pretreatment SPECT can assess tissue reversibility and increase the efficacy of intra-arterial thrombolysis for acute stroke patients.